Top Institutional Investors

Opaleye Management Inc. — 13F Holdings & Portfolio

CIK 1595855 · latest 13F-HR filed 2026-08-14

Backtest portfolio

Opaleye Management Inc. manages $1.10B in 13F-reported U.S. long-equity assets across 58 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LQDA (17.67%), ETON (9.38%), HROW (9.23%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 13 new positions and exited 9; 29 existing positions rose in reported value and 11 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$1.10B

Long-equity book

Holdings
58

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+13 / −9 / ↑29 / ↓11

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
LQDA17.7% · -4%ETON9.4% · 0%HROW9.2% · -15%IRON5.7% · +103%URGN4.8% · +1%APGE4.7% · 0%MGTX4.3% · +67%SLGL3.4% · 0%RZLT3.0% · 0%TGTX2.7% · 0%IMMX2.2% · newCBIO2.2% · +0%STOK2.1% · 0%ACOG1.9% · +13%EWTX1.8% · 0%RVMD1.7% · 0%GLUE1.6% · newALMS1.4% · 0%CDXS1.4% · 0%REPL1.4% · newXOMA1.3% · +13%MBX1.3% · 0%RYTM1.2% · -0%EDIT1.1% · +100%PTGX1.1% · 0%CABA1.1% · +180%QTTB1.1% · -26%ANNX0.9% · -26%VSTM0.6% · newZNTL0.6% · 0%RLMD0.6% · 0%OCUL0.5% · 0%TRVI0.5% · -10%BBOT0.5% · +1214%LYEL0.4% · +335%IRD0.4% · +0%FDMT0.4% · +198%NTLA0.4% · +2%VYGR0.4% · +3%BDSX0.4% · -24%RCKT0.3% · +5%JBIO0.3% · -66%SNWV0.3% · -69%FBIO0.2% · -15%DERM0.2% · -64%PHAT0.2% · newINBX0.2% · newENTA0.2% · 0%COAG0.2% · newTRAX0.1% · newCGON0.1% · -81%BHVN0.1% · newAVIR0.1% · -27%KTTA0.1% · newADCT0.1% · newOKYO0.1% · newPTN0.0% · newADGM0.0% · 0%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

3 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 64.8%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Feb 19, 2026.

Assets Under Management
$802.8M
Discretionary
$802.8M
Employees
4
Accounts
2
Address
ONE BOSTON PLACE
26TH FLOOR
BOSTON, MA 02108
Phone
(617) 229-5085
This firm reports 1 disclosure item on its registration.
Name Title / Status Ownership Type
SILVERMAN, JAMES, AARON ControlPRESIDENT/CHIEF COMPLIANCE OFFICER
since Feb 1996
75% or moreIndividual

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Opaleye Management Inc. Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 LIQUIDIA CORPORATION LQDA 53635D202 $195.1M 17.67% 2,447,500 SH
2 ETON PHARMACEUTICALS INC ETON 29772L108 $103.5M 9.38% 2,860,000 SH
3 HARROW INC HROW 415858109 $101.9M 9.23% 2,400,000 SH
4 DISC MEDICINE INC IRON 254604101 $62.5M 5.66% 855,000 SH
5 UROGEN PHARMA LTD URGN M96088105 $53.0M 4.80% 1,439,996 SH
6 APOGEE THERAPEUTICS INC APGE 03770N101 $51.8M 4.69% 390,000 SH
7 MEIRAGTX HLDGS PLC MGTX G59665102 $48.0M 4.34% 3,550,000 SH
8 SOL-GEL TECHNOLOGIES LTD SLGL M8694L137 $37.1M 3.36% 500,000 SH
9 REZOLUTE INC RZLT 76200L309 $32.8M 2.97% 6,300,000 SH
10 TG THERAPEUTICS INC TGTX 88322Q108 $29.4M 2.66% 535,000 SH
11 IMMIX BIOPHARMA INC IMMX 45258H106 $24.2M 2.19% 2,345,000 SH
12 CRESCENT BIOPHARMA INC. CBIO G2545C104 $23.7M 2.15% 1,319,351 SH
13 STOKE THERAPEUTICS INC STOK 86150R107 $22.9M 2.07% 700,000 SH
14 ALPHA COGNITION INC ACOG 02074J501 $20.9M 1.89% 2,895,467 SH
15 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $20.3M 1.84% 500,000 SH
16 REVOLUTION MEDICINES INC RVMD 76155X100 $18.7M 1.70% 100,000 SH
17 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $18.0M 1.63% 745,000 SH
18 ALUMIS INC ALMS 022307102 $15.5M 1.40% 550,000 SH
19 CODEXIS INC CDXS 192005106 $15.3M 1.39% 6,785,000 SH
20 REPLIMUNE GROUP INC REPL 76029N106 $15.3M 1.39% 1,384,993 SH
21 XOMA ROYALTY CORPORATION XOMA 98419J206 $14.4M 1.30% 338,374 SH
22 MBX BIOSCIENCES INC MBX 55287L101 $14.4M 1.30% 260,000 SH
23 RHYTHM PHARMACEUTICALS INC RYTM 76243J105 $13.6M 1.23% 122,500 SH
24 EDITAS MEDICINE INC EDIT 28106W103 $12.5M 1.13% 3,861,930 SH
25 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $12.3M 1.11% 100,000 SH
26 CABALETTA BIO INC CABA 12674W109 $12.0M 1.09% 3,863,800 SH
27 Q32 BIO INC QTTB 746964105 $11.9M 1.07% 931,000 SH
28 ANNEXON INC ANNX 03589W102 $9.8M 0.89% 1,714,451 SH
29 VERASTEM INC VSTM 92337C203 $6.9M 0.62% 1,800,000 SH
30 ZENTALIS PHARMACEUTICALS INC ZNTL 98943L107 $6.9M 0.62% 1,412,656 SH
31 RELMADA THERAPEUTICS INC RLMD 75955J402 $6.5M 0.59% 935,000 SH
32 OCULAR THERAPEUTIX INC OCUL 67576A100 $5.9M 0.53% 600,000 SH
33 TREVI THERAPEUTICS INC TRVI 89532M101 $5.8M 0.52% 310,000 SH
34 BRIDGEBIO ONCOLOGY THERAPEUT BBOT 107924102 $5.3M 0.48% 700,000 SH
35 LYELL IMMUNOPHARMA INC LYEL 55083R203 $4.8M 0.44% 344,025 SH
36 OPUS GENETICS INC IRD 67577R102 $4.6M 0.42% 1,125,000 SH
37 4D MOLECULAR THERAPEUTICS IN FDMT 35104E100 $4.4M 0.40% 334,437 SH
38 INTELLIA THERAPEUTICS INC NTLA 45826J105 $4.2M 0.38% 250,000 SH
39 VOYAGER THERAPEUTICS INC VYGR 92915B106 $4.1M 0.38% 1,185,000 SH
40 BIODESIX INC BDSX 09075X207 $4.1M 0.37% 180,000 SH
41 ROCKET PHARMACEUTICALS INC RCKT 77313F106 $3.4M 0.31% 1,000,000 SH
42 JADE BIOSCIENCES INC JBIO 008064206 $3.2M 0.29% 145,000 SH
43 SANUWAVE HEALTH INC SNWV 80303D305 $3.1M 0.28% 306,140 SH
44 FORTRESS BIOTECH INC FBIO 34960Q307 $2.7M 0.25% 890,000 SH
45 JOURNEY MED CORP DERM 48115J109 $2.5M 0.22% 350,000 SH
46 PHATHOM PHARMACEUTICALS INC PHAT 71722W107 $2.0M 0.18% 185,589 SH
47 INHIBRX BIOSCIENCES INC INBX 45720N103 $1.9M 0.17% 20,291 SH
48 ENANTA PHARMACEUTICALS INC ENTA 29251M106 $1.8M 0.17% 125,000 SH
49 HEMAB THERAPEUTICS HLDGS INC COAG 423494103 $1.8M 0.16% 47,652 SH
50 FIRST TRACKS BIOTHERAPEUTICS TRAX 337185102 $1.3M 0.12% 65,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $1.10B 58 0001420506-26-001803
2026-03-31 2026-05-15 $759.2M 54 0001420506-26-001151
2025-12-31 2026-04-13 $757.9M 54 0001493152-26-016299
2025-12-31 2026-02-17 $758.0M 54 0001493152-26-007085
Filer Information
Address
ONE BOSTON PLACE
SUITE 2600
BOSTON, MA 02108
Phone
(617) 904-9195
Filing Manager
Opaleye Management Inc.
BOSTON, MA
Signatory
James Silverman
President